Tags

Type your tag names separated by a space and hit enter

Therapeutic options in the treatment of tinea capitis.
Expert Opin Pharmacother. 2004 Feb; 5(2):219-27.EO

Abstract

Tinea capitis is primarily a disease of pre-adolescent children. In North America and the UK, Trichophyton tonsurans is responsible for > 90% of cases. Microsporum canis is the predominant pathogen in certain parts of Europe. The standard of care for the treatment of tinea capitis is oral griseofulvin and so far, it remains the only medication approved by the US FDA for this condition. The newer oral antifungal agents, such as terbinafine, itraconazole and fluconazole, appear to be effective, safe and have the advantage of a shorter treatment duration. Although a significant number of clinical trials and reports have documented experience with terbinafine and itraconazole for the treatment of tinea capitis, it should be noted that only a few trials have been conducted utilising fluconazole. Both 2% ketoconazole and 1% selenium sulfide shampoos have been shown to reduce surface colony counts of dermatophytes in infected individuals, and these agents are often recommended for adjuvant therapy. This article reviews data currently available on various therapeutic alternatives for the treatment of tinea capitis and summarises all relevant clinical trials that have thus far investigated the use of these drugs for tinea capitis in the paediatric population.

Authors+Show Affiliations

Division of Pediatric Dermatology, Children's Hospital, San Diego, CA 92123, USA. ycchan@nsc.gov.sgNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

14996619

Citation

Chan, Yuin-Chew, and Sheila F. Friedlander. "Therapeutic Options in the Treatment of Tinea Capitis." Expert Opinion On Pharmacotherapy, vol. 5, no. 2, 2004, pp. 219-27.
Chan YC, Friedlander SF. Therapeutic options in the treatment of tinea capitis. Expert Opin Pharmacother. 2004;5(2):219-27.
Chan, Y. C., & Friedlander, S. F. (2004). Therapeutic options in the treatment of tinea capitis. Expert Opinion On Pharmacotherapy, 5(2), 219-27.
Chan YC, Friedlander SF. Therapeutic Options in the Treatment of Tinea Capitis. Expert Opin Pharmacother. 2004;5(2):219-27. PubMed PMID: 14996619.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic options in the treatment of tinea capitis. AU - Chan,Yuin-Chew, AU - Friedlander,Sheila F, PY - 2004/3/5/pubmed PY - 2004/6/25/medline PY - 2004/3/5/entrez SP - 219 EP - 27 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 5 IS - 2 N2 - Tinea capitis is primarily a disease of pre-adolescent children. In North America and the UK, Trichophyton tonsurans is responsible for > 90% of cases. Microsporum canis is the predominant pathogen in certain parts of Europe. The standard of care for the treatment of tinea capitis is oral griseofulvin and so far, it remains the only medication approved by the US FDA for this condition. The newer oral antifungal agents, such as terbinafine, itraconazole and fluconazole, appear to be effective, safe and have the advantage of a shorter treatment duration. Although a significant number of clinical trials and reports have documented experience with terbinafine and itraconazole for the treatment of tinea capitis, it should be noted that only a few trials have been conducted utilising fluconazole. Both 2% ketoconazole and 1% selenium sulfide shampoos have been shown to reduce surface colony counts of dermatophytes in infected individuals, and these agents are often recommended for adjuvant therapy. This article reviews data currently available on various therapeutic alternatives for the treatment of tinea capitis and summarises all relevant clinical trials that have thus far investigated the use of these drugs for tinea capitis in the paediatric population. SN - 1465-6566 UR - https://www.unboundmedicine.com/medline/citation/14996619/Therapeutic_options_in_the_treatment_of_tinea_capitis_ L2 - http://www.tandfonline.com/doi/full/10.1517/14656566.5.2.219 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.